Results 181 to 190 of about 46,868 (196)
Some of the next articles are maybe not open access.
2018
Abstract Ventricular assist devices (VADs) have become a cornerstone of therapy in the management of end-stage heart failure, both as a means of bridging to cardiac transplantation and as destination therapy for long-term quality of life improvement.
Rajagopala Padmanabhan, Penny Sappington
openaire +2 more sources
Abstract Ventricular assist devices (VADs) have become a cornerstone of therapy in the management of end-stage heart failure, both as a means of bridging to cardiac transplantation and as destination therapy for long-term quality of life improvement.
Rajagopala Padmanabhan, Penny Sappington
openaire +2 more sources
1995
Extracardiac blood pumps may be used to allow temporary circulatory support in circumstances in which the pumping function of the heart is inadequate. Because of the complexity of these devices, the complications associated with their use, and cost considerations, all pharmacologic avenues of myocardial and circulatory support, as well as the ...
Bradley L. Bufkin, Robert A. Guyton
openaire +1 more source
Extracardiac blood pumps may be used to allow temporary circulatory support in circumstances in which the pumping function of the heart is inadequate. Because of the complexity of these devices, the complications associated with their use, and cost considerations, all pharmacologic avenues of myocardial and circulatory support, as well as the ...
Bradley L. Bufkin, Robert A. Guyton
openaire +1 more source
Kyobu geka. The Japanese journal of thoracic surgery, 2010
There are 2 kinds of artificial heart used for clinical patients with end-stage heart failure. One is a ventricular assist device (VAD) and the other is a total artificial heart (TAH). Only paracorporeal VADs are commercially available currently in Japan, such as Toyobo VAD and BVS 5000. Paracorporeal Zeon VAD and implantable Novacor LVAD were approved
Shunei, Kyo, S, Takamoto
openaire +1 more source
There are 2 kinds of artificial heart used for clinical patients with end-stage heart failure. One is a ventricular assist device (VAD) and the other is a total artificial heart (TAH). Only paracorporeal VADs are commercially available currently in Japan, such as Toyobo VAD and BVS 5000. Paracorporeal Zeon VAD and implantable Novacor LVAD were approved
Shunei, Kyo, S, Takamoto
openaire +1 more source
2016
Clinical History Image Findings Discussion Find Diagnosis Differential ...
openaire +1 more source
Clinical History Image Findings Discussion Find Diagnosis Differential ...
openaire +1 more source
Kyobu geka. The Japanese journal of thoracic surgery, 2017
In Japan the 1st paracorporeal ventricular assist device (VAD) was implanted in 1980. Since then, more than 2,000 VADs were used. Small size continuous-flow VAD (CFVAD) was developed in 1990s, which dramatically improved safety and efficacy of long-term support.
openaire +1 more source
In Japan the 1st paracorporeal ventricular assist device (VAD) was implanted in 1980. Since then, more than 2,000 VADs were used. Small size continuous-flow VAD (CFVAD) was developed in 1990s, which dramatically improved safety and efficacy of long-term support.
openaire +1 more source